Advertisement

Topics

Latest "Hutchison China Meditech Limited Positive Fruquintinib Pivotal Phase" News Stories

00:20 EST 15th December 2018 | BioPortfolio

Here are the most relevant search results for "Hutchison China Meditech Limited Positive Fruquintinib Pivotal Phase" found in our extensive news archives from over 250 global news sources.

More Information about Hutchison China Meditech Limited Positive Fruquintinib Pivotal Phase on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Hutchison China Meditech Limited Positive Fruquintinib Pivotal Phase for you to read. Along with our medical data and news we also list Hutchison China Meditech Limited Positive Fruquintinib Pivotal Phase Clinical Trials, which are updated daily. BioPortfolio also has a large database of Hutchison China Meditech Limited Positive Fruquintinib Pivotal Phase Companies for you to search.

Showing "Hutchison China Meditech Limited Positive Fruquintinib Pivotal Phase" News Articles 1–25 of 17,000+

Friday 14th December 2018

Cerveau Announces Singapore Test of Neuro PET Imaging Agent

Cerveau Technologies, a partnership between Beijing Sinotau Pharma and Enigma Biomedical of Toronto, will start a Singapore trial of its PET imaging agent for neurofibrillary tangles (NFTs) in the brain, the first Asia test of the agent. Cerveau develops diagnostics and technology for neurodegenerative disorders including Alzheimer's disease. It in-licensed global rights to the agent, MK-6240, fro...


Psoriatic Arthritis Global Clinical Trials Review, H1, 2018 [Report Updated: 29062018] Prices from USD $2125

Psoriatic Arthritis Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Psoriatic Arthritis Global Clinical Trials Review, H1, 2018" provides an overview of Psoriatic Arthritis clinical trials scenario. This report provides top line data relating to the clinical trials on Psoriatic Arthritis. Report includes an overview of trial numbers and their average enrollment in...

China introduces ‘social’ punishments for scientific misconduct


Traveler's Diarrhea Global Clinical Trials Review, H2, 2018 [Report Updated: 31082018] Prices from USD $2125

Traveler's Diarrhea Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Traveler's Diarrhea Global Clinical Trials Review, H2, 2018" provides an overview of Traveler's Diarrhea clinical trials scenario. This report provides top line data relating to the clinical trials on Traveler's Diarrhea. Report includes an overview of trial numbers and their average enrollment in...

Si è conclusa a Ya'an la seconda conferenza sul marketing dei nuovi media dedicati al turismo ...

- La China Giant Panda Culture Alliance è stata formalmente lanciata YA'AN, Cina, 15 dicembre 2018 /PRNewswire/ --Si sono concluse il 6 dicembre a Ya'an, Read more...

Drug Discovery Group encouraged by trials progress

Drug discovery group Evgen Pharma said it was delighted by progress on treatments under development when it announced its interim results for the six months to September 30 today. The AIM-listed business, which has offices in Wilmslow and Liverpool Science Park, focuses on treatments for cancer, strokes and Multiple Sclerosis. It said it released positive interim data from its ongoing clinical stu...

Lifetech Scientific Shenzhen Co Ltd Product Pipeline Analysis, 2018 Update [Report Updated: 06122018] Prices from USD $750

SummaryLifetech Scientific Shenzhen Co Ltd Lifetech Shenzhen, a subsidiary of Lifetech Scientific Corp, is a medical device company that offers minimally invasive interventional medical devices for cardiovascular and peripheral vascular diseases. The company provides products such as dilator, occluders, delivery system, bioprosthetic heart valve and sizing ballon, among others. It offers products ...

Angetrieben von Qualität: GAC Motor schafft solide Grundlage für Internationalisierungsstrategie

GUANGZHOU, China, 14. Dezember 2018 /PRNewswire/ -- GAC Motor, der am schnellsten wachsende Automobilhersteller Chinas, hat seinen Qualitätsbericht für das Jahr 2018 vorgelegt, der die Read more...

Impulsionada pela qualidade: a GAC Motor implanta base sólida para sua estratégia de ...

GUANGZHOU, China, 14 de dezembro de 2018 /PRNewswire/ -- A GAC Motor, a fabricante de automóveis de crescimento mais rápido da China, publicou seu relatório Read more...

Impulsada por la calidad, GAC Motor muestra bases sólidas para su estrategia de ...

GUANGZHOU, China, 14 de diciembre de 2018 /PRNewswire/ -- GAC Motor, la automotriz de más rápido crecimiento de China, presentó su informe de calidad 2018, Read more...

Manx Telecom (158355634MANX) - Worth listening out for clearSound

Edison Investment Research - Technology - Manx Telecom: In September, Manx Telecom (MT) subsidiary Goshawk announced the launch of clearSound (MTcS), an innovative mobile phone service for people with hearing needs. Following positive feedback from test groups, MT has signed a deal with BT/EE to launch the Goshawk proposition on their UK networks and it intends invest £10m on the launch over ...

Psychosis Global Clinical Trials Review, H1, 2018 [Report Updated: 29062018] Prices from USD $2125

Psychosis Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Psychosis Global Clinical Trials Review, H1, 2018" provides an overview of Psychosis clinical trials scenario. This report provides top line data relating to the clinical trials on Psychosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the glob...

China Anesthesia and Respiratory Devices Market Outlook to 2025 Anesthesia Machines, Airway and Anesthesia Devices, Respiratory Devices and Others [Report Updated: 19102018] Prices from USD $5096

China Anesthesia and Respiratory Devices Market Outlook to 2025 Anesthesia Machines, Airway and Anesthesia Devices, Respiratory Devices and OthersSummaryGlobalData's new report, China Anesthesia and Respiratory Devices Market Outlook to 2025, provides key market data on the China Anesthesia and Respiratory Devices market. The report provides value, in millions of US dollars, volume in units and a...

China Biologic Announces Dismissal of Lawsuit Filed in Cayman Islands by Former Chairman

BEIJING, Dec. 14, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Grand Court of the Cayman Islands (the "Court") dismissed the lawsuit previously filed against the Company by Mr. David (Xiaoying) Gao...

Un clima de negocios cada vez más beneficioso atrae más inversores de todo el mundo a Dongguán

DONGGUÁN, China, 14 de diciembre de 2018 /PRNewswire/ -- La Convención Mundial de Empresarios de Dongguán 2018 se celebró en la ciudad homónima entre el Read more...

Traumatic Pain Global Clinical Trials Review, H2, 2018 [Report Updated: 31082018] Prices from USD $2125

Traumatic Pain Global Clinical Trials Review, H2, 2018SummaryGlobalData's clinical trial report, Traumatic Pain Global Clinical Trials Review, H2, 2018" provides an overview of Traumatic Pain clinical trials scenario. This report provides top line data relating to the clinical trials on Traumatic Pain. Report includes an overview of trial numbers and their average enrollment in top countries condu...

More Evidence of HPV Link to Cervical Cancer

(MedPage Today) -- Positive test IDs high-risk women with normal cervical cytology

The world's first gene-edited babies were born in China last month. The same gene-editing tool, applied on animals, has resulted in long tongues, extra bones, dappled fleeces and deaths. My latest @WSJ investigation with @Lucy_Craymer. https://www.wsj.co

The world's first gene-edited babies were born in China last month. The same gene-editing tool, applied on animals, has resulted in long tongues, extra bones, dappled fleeces and deaths. My latest @WSJ investigation with @Lucy_Craymer. https://www.wsj.com/articles/deformities-alarm-scientists-racing-to-rewrite-animal-dna-11544808779 …

J&J kept a guiding hand on talc safety research

Johnson & Johnson developed a strategy in the 1970s to deal with a growing volume of research showing that talc miners had elevated rates of lung disease and cancer: Promote the positive, challenge the negative.

Idera Pharmaceuticals Presents Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial

Idera Pharmaceuticals  (NASDAQ:IDRA) is presenting data from the ongoing phase 2 expansion of the ILLUMINATE-204 trial investigating tilsotolimod, Idera’s intratumorally-delivered toll-like receptor 9 (TLR9) agonist, in combination with ipilimumab (Yervoy). As quoted in the press release: “The results from this combination are among the most promising we have seen in this challenging populati...

MÄRKTE USA/Konjunktursorgen belasten - Johnson & Johnson brechen ein

Von Thomas Rossmann NEW YORK (Dow Jones)--Die Unsicherheit um das weltweite Konjunkturwachstum drückt zum Wochenausklang auf die Stimmung an der Wall Street. Mit schwachen Daten aus China seien be...

OKC Dentist Changes Dental Office Name to Grace Jun Dentistry

After opening her doors for just over one year, Dr. Grace Jun has changed her dental office name to Grace Jun Dentistry from Grace Dentistry to better distinguish her practice. Grace Jun Dentistry provides a range of services from family/general dentistry to restorative to cosmetic dentistry in Oklahoma City. Get to know Dr. Grace, her philosophy on patient care, and her journey into the dental wo...

Trastuzumab Biosimilar CT-P6 Shows Comparable Efficacy at 2-Year Follow-up

CT-P6, a proposed biosimilar to trastuzumab, exhibited long-term disease-free survival and overall survival similar to the reference product in the treatment of patients with HER2-positive early breast cancer.

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

– If Authorized in Europe, ADCETRIS in Combination with AVD (Adriamycin, Vinblastine and Dacarbazine) Will Be the First New Treatment Regimen Available for Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Decades – – Opinion Based on Positive Phase 3 ECHELON-1 Study Results, Which Demonstrated ADCETRIS Combination ...

Terumo Corporation Strategy, SWOT and Corporate Finance Report [Report Updated: 26112018] Prices from USD $175

Terumo Corporation Strategy, SWOT and Corporate Finance ReportSummaryTerumo Corporation Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360 view of the company.Key HighlightsTerumo Corporation Terumo or 'the ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks